| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | Entrez:55507 MIM:607437 HGNC:HGNC:13310 Ensembl:ENSG00000111291 AllianceGenome:HGNC:13310 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | G protein-coupled receptor class C group 5 member D | |||||
| GTO ID | GTC3696 |
| Trial ID | NCT06182696 |
| Disease | Multiple Myeloma |
| Altered gene | GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | OriCAR-017 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma |
| Year | 2023 |
| Country | China |
| Company sponsor | OriCell Therapeutics Co., Ltd. |
| Other ID(s) | OriCAR-017-P1 |
| Cohort 1 | |||||||||
|
|||||||||